Heart failure with preserved ejection fraction based on aging and comorbidities

被引：0
作者：
Ying Lin
Shihui Fu
Yao Yao
Yulong Li
Yali Zhao
Leiming Luo
机构：
[1] Hainan Hospital of Chinese People’s Liberation Army General Hospital,Department of Cardiology
[2] Chinese People’s Liberation Army General Hospital,Department of Geriatric Cardiology
[3] Medical School of Duke University,Centre for the Study of Ageing and Human Development and Geriatrics Division
[4] National School of Development,Centre for Healthy Ageing and Development Studies
[5] Peking University,Central Laboratory
[6] Hainan Hospital of Chinese People’s Liberation Army General Hospital,undefined
来源：
Journal of Translational Medicine | / 19卷
关键词：
Aging; Comorbidities; Diagnosis; Heart failure with preserved ejection fraction; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be established based on left ventricular ejection fraction and may benefit from individually tailored approaches, underlying age-related changes and frequent comorbidities. Compared with the rapid development in the treatment of heart failure with reduced ejection fraction, HFpEF presents a great challenge and needs to be addressed considering the failure of HF drugs to improve its outcomes. Further extensive studies on the relationships between HFpEF, aging, and comorbidities in carefully phenotyped HFpEF subgroups may help understand the biology, diagnosis, and treatment of HFpEF. The current review summarized the diagnostic and therapeutic development of HFpEF based on the complex relationships between aging, comorbidities, and HFpEF.
引用
收藏
相关论文
共 377 条
  • [1] Ponikowski P(2016)2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur Heart J 37 2129-2200
  • [2] Paulus W(2013)A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and Remodeling through coronary microvascular endothelial inflammation J Am Coll Cardiol 62 263-271
  • [3] Tschope C(2007)Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry J Am Coll Cardiol 50 768-777
  • [4] Fonarow GC(2016)The HFpEF obesity phenotype: the elephant in the room J Am Coll Cardiol 68 200-203
  • [5] Kitzman DW(2019)PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction N Engl J Med 381 1609-1620
  • [6] Shah SJ(2019)Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes: results from the CANVAS program Circulation 139 2591-2593
  • [7] Solomon SD(2018)Epicardial fat in heart failure patients with mid-range and preserved ejection fraction Eur J Heart Fail 20 1559-1566
  • [8] Figtree GA(2018)Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat JACC Clin Electrophysiol 4 1529-1540
  • [9] van Woerden G(2018)Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF Eur Heart J 39 3439-3450
  • [10] Gorter TM(2018)Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction JACC Cardiovasc Imaging 12 2291-2301
12345678910